Onglyza Data From Sentinel Pilot Can Be Validated By Phase IV Trial, FDA Says

Bristol-Myers Squibb/AstraZeneca’s type 2 diabetes treatment Onglyza (saxagliptin) has been chosen as the focus of the first drug evaluation in the mini-Sentinel active safety surveillance project in part because observational findings on the drug can be compared to a large Phase IV clinical trial now under way.